| Post | Subject | | |
|
#404
|
NVS/GMAB—FDA approves Kesimpta—(subcutaneous ofatumumab)—for MS:
|
DewDiligence
| 08/20/20 03:09:09 PM |
|
#403
|
Ofatumumab PFUFA delayed 3mo—>Sep 2020 for MS indication:
|
DewDiligence
| 06/02/20 04:35:06 PM |
|
#402
|
What am I missing here? Why is no
|
fung_derf
| 05/19/20 09:57:59 AM |
|
#401
|
NVS concedes Beovu has new safety issue:
|
DewDiligence
| 04/09/20 12:22:26 PM |
|
#400
|
Ok thank you
|
Maddog 112
| 03/23/20 07:03:30 AM |
|
#399
|
It won't have any effect at all on
|
DewDiligence
| 03/22/20 10:26:35 PM |
|
#398
|
How much will this affect the stock price
|
Maddog 112
| 03/22/20 10:13:54 PM |
|
#397
|
Yes—that was announced on Friday: #msg-154462215.
|
DewDiligence
| 03/22/20 10:09:51 PM |
|
#396
|
Is it true NVS to supply 160 mil
|
Maddog 112
| 03/22/20 09:43:52 PM |
|
#395
|
More on the same story (Beovu safety):
|
DewDiligence
| 02/25/20 11:04:06 AM |
|
#394
|
Acceptance of a BLA/NDA application for review doesn’t
|
DewDiligence
| 02/25/20 07:17:30 AM |
|
#393
|
And so this got ignored. :-(
|
Ecomike
| 02/24/20 09:32:15 PM |
|
#392
|
The cause is a safety update re Beovu
|
DewDiligence
| 02/24/20 02:40:46 PM |
|
#391
|
5.5% drop on a biotech drug firm like
|
Ecomike
| 02/24/20 02:35:21 PM |
|
#390
|
NVS 12/5/19 R&D Day slides:
|
DewDiligence
| 12/08/19 06:53:17 PM |
|
#389
|
NVS PR in conjunction with R&D Day investor webcast:
|
DewDiligence
| 12/05/19 07:37:24 PM |
|
#388
|
These shares are a BUY - Up and
|
elotto777
| 11/26/19 12:02:02 PM |
|
#387
|
NVS acquires MDCO for $85/sh cash—a 64% premium
|
DewDiligence
| 11/24/19 03:47:35 PM |
|
#386
|
CHMP approves NVS’ Mayzent for SPMS:
|
DewDiligence
| 11/15/19 09:57:19 AM |
|
#385
|
News: $NVS ROSEN, A LEADING GLOBAL LAW FIRM,
|
whytestocks
| 11/09/19 08:45:26 PM |
|
#384
|
FDA approves NVS’ Beovu—(a/k/a brolucizumab/RTH258) for wet AMD—3mo
|
DewDiligence
| 10/08/19 10:18:25 AM |
|
#383
|
Here's the cause of today's sell-off:
|
DewDiligence
| 08/06/19 03:10:04 PM |
|
#382
|
Any clue what too the air out this
|
Ecomike
| 08/06/19 03:04:54 PM |
|
#381
|
I would love to hear more about that
|
Ecomike
| 07/12/19 11:54:34 AM |
|
#380
|
Novartis been researching PS Phosphatidylserine targeting ?
|
biopharm
| 05/28/19 07:41:28 AM |
|
#379
|
Green after hours trading
|
PennyStock Alert
| 05/25/19 11:46:59 AM |
|
#378
|
Nice news !
|
PennyStock Alert
| 05/24/19 02:02:44 PM |
|
#377
|
News: $NVS AveXis receives FDA approval for Zolgensma®,
|
whytestocks
| 05/24/19 01:20:40 PM |
|
#376
|
NVS Investor Day slides:
|
DewDiligence
| 05/23/19 11:43:54 AM |
|
#375
|
NVS PR accompanying today’s Investor Day webcast:
|
DewDiligence
| 05/23/19 11:30:11 AM |
|
#374
|
NVS’ QVM149* scores in phase-2 asthma trial, showing
|
DewDiligence
| 05/22/19 12:30:29 PM |
|
#373
|
NVS acquires Xiidra from Takeda for $3.4B up-front
|
DewDiligence
| 05/08/19 07:23:44 PM |
|
#372
|
AMGN and NVS are at war over Aimovig,
|
DewDiligence
| 05/02/19 07:26:40 PM |
|
#371
|
NVS shares declined on 4/9/19 by the implied
|
DewDiligence
| 04/26/19 05:34:15 PM |
|
#370
|
Higher PE sounds sweet :-)
|
Ecomike
| 04/26/19 05:00:39 PM |
|
#369
|
The ALC spin-off did not benefit NVS itself
|
DewDiligence
| 04/26/19 04:41:54 PM |
|
#368
|
DD, do you know what if anything NVS
|
Ecomike
| 04/26/19 04:25:41 PM |
|
#367
|
NVS completes separation of Alcon, which is now
|
DewDiligence
| 04/09/19 06:41:47 PM |
|
#366
|
NVS sues AMGN re Aimovig collaboration termination:
|
DewDiligence
| 04/04/19 02:50:48 PM |
|
#365
|
FDA approves NVS’ Mayzent* for MS—including SPMS:
|
DewDiligence
| 03/26/19 07:49:22 PM |
|
#364
|
If NVS Does BO AMRN,
|
Invest83838
| 02/22/19 11:32:46 AM |
|
#363
|
WSJ opines on the “new” Novartis:
|
DewDiligence
| 11/19/18 11:06:25 AM |
|
#362
|
NVS R&D Day slides (170 pages):
|
DewDiligence
| 11/05/18 08:53:13 AM |
|
#361
|
PFE-NVS clinical-trial collaboration in NASH: #msg-144519047.
|
DewDiligence
| 10/29/18 10:14:56 AM |
|
#360
|
NVS 3Q18 results:
|
DewDiligence
| 10/18/18 04:05:46 PM |
|
#359
|
NVS receives CRL for Ilaris in CVD: #msg-144301592.
|
DewDiligence
| 10/18/18 10:34:34 AM |
|
#358
|
NVS acquires ECYT for $2.1B:
|
DewDiligence
| 10/18/18 10:33:30 AM |
|
#357
|
AMGN, NVS launch Humira biosimilars in Europe, pursuant
|
DewDiligence
| 10/16/18 11:24:18 AM |
|
#356
|
ABBV settles global Humira-patent litigation with NVS: #msg-144157243.
|
DewDiligence
| 10/11/18 05:24:02 PM |
|
#355
|
PDUFA date for NVS’ BAF312 in SPMS—>Mar 2019
|
DewDiligence
| 10/08/18 10:01:36 AM |
| Post | Subject | | |